Semax Where to Buy: The Standards You Have to Set Yourself

Semax where to buy is a harder question than it looks, because the answer most people expect is not available at any price. There is no pharmacy counter, no prescriber and no regulator holding a release specification for this compound, which means the acceptance criteria are yours to write. A vendor either publishes evidence that meets them or it does not.

It helps to be precise about what you are sourcing. Semax is a synthetic heptapeptide, seven residues in the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is the ACTH(4-7) fragment with a Pro-Gly-Pro tail added to slow enzymatic breakdown, registered at PubChem CID 9811102 with the formula C37H51N9O10S and a molecular weight of 813.9. It is often described as a tuftsin analogue, and that is simply a different peptide: Selank, the other Russian heptapeptide, has a different sequence and a different origin. The two are confused constantly, including by pages selling them.

One supplier is linked on this page and we earn a commission if you buy through it, which our affiliate disclosure sets out in full. The scoring further down includes the criteria that supplier meets and the question its certificate cannot answer.

With an approved medicine, most of the sourcing work is already done by the time you arrive. A manufacturer holds an approval, a monograph or an approved specification defines what the product must contain, every batch is released against that specification, and a licensed pharmacy sits in the chain with a recall path attached to it. Semax has none of that in the United States, and it holds no FDA approval for any indication.

The compounded prescription route is closed too, and the reason is worth stating precisely because competing pages garble it. A pharmacy compounding under section 503A of the Federal Food, Drug and Cosmetic Act may work from a bulk drug substance only if that substance complies with a United States Pharmacopeia or National Formulary monograph, or is a component of an FDA-approved drug product, or appears on FDA's 503A bulks list. FDA sets out that three-part test on its bulk drug substances page, content current as of 14 May 2026. Semax fails all three conditions.

The third condition is where the misinformation lives. Semax was nominated for the bulks list, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn. It sits on no current category list at all. Today's category 2 contains six substances, and Semax is not among them. So a page telling you Semax is category 2 is describing a status that ended; a page telling you it is banned has invented a word FDA did not use. Nominated and withdrawn is the accurate description, and the practical effect for a buyer is the same either way, which is that no pharmacy can lawfully compound it.

Not every research peptide sits in that position, which is why the comparison is instructive rather than academic. Our write-up on the compounded route that does exist for NAD+ covers a substance FDA placed in category 1, where the agency has said it does not intend to take action against compounders meeting stated conditions. Semax has no equivalent. Any clinic offering to arrange it is operating outside the pharmacy system, whatever the website says.

Since nobody is going to hand you a specification, here is the one we use. Seven criteria, in the order they matter, and each written so that a vendor either satisfies it on a document you can open before paying or fails it.

A batch-specific certificate, published before purchase. Not a generic PDF for the product line, not a certificate emailed after payment, and not a screenshot. The lot number on the document has to be the lot number you can match to the vial that arrives. Everything else on this list is worthless if this one fails, because a certificate describing a different batch describes somebody else's powder.

Purity stated against a written specification. A purity percentage on its own is a number without a pass mark. The certificate should name the method, show the chromatogram, and state the acceptance specification the result was measured against, so that you can see the result cleared a bar rather than simply existing.

Identity, not just purity. Purity tells you how much of the sample is one substance. Identity tells you which substance. For a peptide that means mass spectrometry against the expected mass, and for Semax the expected molecular weight is 813.9. A pure sample of the wrong heptapeptide passes a purity test perfectly.

Endotoxin and sterility, for anything that will be dissolved. This is the criterion FDA's own stated concern points at, and it is the one most certificates in this market skip. Bacterial endotoxin testing detects pyrogenic contamination from gram-negative bacteria that survives sterilisation; a microbial screen asks whether anything grows. Neither is implied by a high purity figure.

Domestic stock and a real returns policy. A parcel that does not cross a border cannot be seized at one, and FDA's personal importation guidance is clear that an unapproved drug offered for import may be refused entry. A refused parcel is not a refund. Card payment to a US business leaves a chargeback route; a bank transfer or a crypto payment ends your recourse the moment it clears.

No human-use claims anywhere on the site. This one reads backwards to most buyers and it is the most reliable tell on the list. A seller making therapeutic claims for an unapproved drug is telling you it is willing to say untrue things in writing, on the page you are being asked to trust.

Ascension Peptides sells Semax as a 10 mg lyophilised vial and publishes a four-page combined certificate of analysis for batch 30-05260628. It is worth opening before you read the table, because the point of this exercise is that you can check the claims rather than take ours.

Purity is reported at 99.886 percent against a stated specification of greater than 98 percent, which is the shape a purity claim should take: a result, a method and a bar it had to clear. The endotoxin result is the unusual part. Testing is by kinetic chromogenic LAL assay to USP Chapter 85, against an E. coli O111:B4 standard over a detection range of 0.01 to 1.0 EU/mL, reporting under 0.20 EU/mL against a 0.5 EU/mL acceptance limit. The microbial sterility screen reports no growth.

That combination is not the norm in this market, and it arrived with a batch rather than with a product. The same vendor's own February Semax certificate carries neither test, and its Selank listing shows the same February-to-June change. Scope is a batch question, so open every certificate on a product page rather than only the one that is a clickable link: the fuller document is often sitting there as an image while the link still points at the older, thinner PDF. That habit is more useful than any vendor ranking, because it is what you carry to the next seller.

The commercial terms, verified on the listing on 21 August 2026: $59.99 for the 10 mg vial, $30.00 with the code PEPTIDEDECK, which works out at $3.00 per milligram. Buying 3, 5 or 10 takes 3 percent, 5 percent or 10 percent off the list price, and free shipping starts at $250. Whether the code and the quantity tiers combine is not documented anywhere we can point to, so do not plan a purchase around the assumption that they do.

Here is the half of this page that a vendor would not write. A batch certificate answers a manufacturing question. It does not answer a safety question, and the distinction matters more for Semax than for most compounds because of what FDA has actually said.

The agency's position, quoted in full from its page on bulk drug substances that may present significant safety risks: "Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."

Read that carefully and you can see exactly how much of the gap a certificate closes. Aggregation and peptide-related impurities are manufacturing and handling problems, and testing is the right instrument for them. A batch that has been assayed for purity, checked for identity, screened for endotoxin and shown no microbial growth has addressed a real part of what FDA named. That is not nothing, and vendors that skip those tests should not get the same credit.

What it does not do is turn an untested substance into a known-safe one. FDA's last sentence is about human safety data, and no certificate of analysis produces human safety data. A clean result on batch 30-05260628 says that batch was well made. It says nothing about what the compound does in a person, which is the question the agency says it cannot answer. Both halves are true at once, and any page giving you only one of them is selling something.

The honest summary is that the criteria above cannot be fully satisfied by anyone, because two of the things a prescription buyer gets for free, an approval and a recall path, do not exist for this compound in any channel. What you can do is refuse to accept less than the criteria that are achievable, which is a batch-specific certificate with purity against a specification, identity by mass, and contamination testing for anything going into solution.

That is a narrow filter and it removes most of the market. It removes the marketplace listings that supply a certificate on request for a batch other than yours. It removes the resellers who repackage bulk powder, which breaks the link between the tested material and the vial in your hand, and which is precisely the step that introduces the aggregation FDA named. It removes the tidy-looking shops with a purity number and no chromatogram.

If you want the same filter applied to a different compound, our guide to sourcing BPC-157 when a clinic has already offered it works through a case where the clinic channel muddies the picture, and the legal position on MOTS-c lands on the same unapproved-but-not-over-the-counter conclusion from a different starting point. The reasoning transfers better than the product names do.